Departments of Psychiatry, Neurology, and Anesthesiology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Bipolar Disord. 2010 Jun;12(4):446-9. doi: 10.1111/j.1399-5618.2010.00818.x.
Medical conditions and associated procedures/treatments may impact therapeutic blood levels of pharmacologic agents in the illnesses we treat. The use of anti-epileptic drugs in the treatment of psychiatric disorders, most commonly bipolar disorders, and epilepsy is a case in point. This report addresses the impact of hemodialysis on lamotrigine efficacy in bipolar disorder.
Case analysis with literature review.
A bipolar disorder patient stabilized on lamotrigine 200 mg total daily dose was admitted to the hospital with end-stage renal disease. With three consecutive days of hemodialysis, treatment-emergent hypomanic features were noted by the patient and confirmed in psychiatric consultation. When lamotrigine was increased to 250 mg total daily dose, the bipolar features remitted.
Lamotrigine titration may be required in bipolar disorder patients undergoing hemodialysis secondary to the associated hemodialysis extraction factor. Therapeutic drug monitoring is recommended in these patients.
医学状况和相关的程序/治疗方法可能会影响我们治疗的疾病中药物的治疗血药浓度。抗癫痫药物在治疗精神疾病,最常见的是双相情感障碍和癫痫中的应用就是一个很好的例子。本报告探讨了血液透析对双相情感障碍中拉莫三嗪疗效的影响。
病例分析并结合文献复习。
一名双相情感障碍患者稳定服用拉莫三嗪 200mg 总日剂量,因终末期肾病住院。经过连续三天的血液透析,患者出现治疗诱发的轻躁狂特征,并在精神科会诊中得到确认。当拉莫三嗪增加到 250mg 总日剂量时,双相特征缓解。
由于相关的血液透析提取因子,接受血液透析的双相情感障碍患者可能需要调整拉莫三嗪的剂量。建议对这些患者进行治疗药物监测。